OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (357)	2/7/2006 8:45:53 PM
From: Miljenko Zuanic	Read Replies (1) of 447

<<It'll be interesting to see if Tarceva gets into 2nd line in Europe as quickly as Goddard suggests.>> EU also has higher smokers rate, so I am not sure about easy penetration. Second, Tarceva is reserved for Platinum failure/resistance population, so all depend on utilization/regime in first line settings. I think that candidate that can re-sensitize platinum/taxol has better chance for second line settings. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next